The objective of this Core is to provide expert advice from the talented team of co-investigators, necessary training, and the infrastructure to utilize molecular biological approaches to create genetically engineered mouse models that will increase the depth and breadth of existing drug abuse research and stimulate new research at Virginia Commonwealth University and throughout the scientific community. Additionally, it will provide a mechanism for scientists both within and outside of the drug abuse field to interact to develop new research projects. Specifically, this Core will provide investigators the necessary training, tools, and expertise to: 1) create novel genetically modified mice, not currently available through other sources;2) maintain mice in a repository in which available mouse lines will be bred, genotyped, and transferred to the investigator upon weaning;3) cryogenically preserve mouse lines for use in future studies;4) develop viral vectors to over-express, knock-down or deliver dominant negative forms of study genes chosen by collaborating investigators;and 5) deliver viral vectors stereotaxically into specific brain regions of interest and verify the extent of the manipulation. Overall this Core will provide new services to multiple investigators, with the goals of providing state-of-the-art molecular biological tools to investigate drugs of abuse, facilitate collaborations, and provide value to drug abuse researchers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
1P30DA033934-01A1
Application #
8577249
Study Section
Special Emphasis Panel (ZDA1-EXL-T (02))
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
1
Fiscal Year
2014
Total Cost
$152,394
Indirect Cost
$50,880
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Poklis, Justin L; Mohs, Amanda J; Wolf, Carl E et al. (2016) Identification of Drugs in Parenteral Pharmaceutical Preparations from a Quality Assurance and a Diversion Program by Direct Analysis in Real-Time AccuTOFTM-Mass Spectrometry (DART-MS). J Anal Toxicol 40:608-616
Poklis, Justin; Poklis, Alphonse; Wolf, Carl et al. (2016) Two Fatal Intoxications Involving Butyryl Fentanyl. J Anal Toxicol 40:703-708
Banks, Matthew L; Smith, Douglas A; Kisor, David F et al. (2016) Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys. Pharmacol Biochem Behav 141:58-65
Grim, T W; Morales, A J; Gonek, M M et al. (2016) Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays. J Pharmacol Exp Ther 359:329-339
Wolf, Carl E; Poklis, Justin L; Cumpston, Kirk et al. (2016) Acute dilated cardiomyopathy and myocardial injury after combined 4-fluoroamphetamine and modafinil ingestion. Drug Test Anal :
Hutsell, Blake A; Baumann, Michael H; Partilla, John S et al. (2016) Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats. Eur Neuropsychopharmacol 26:288-97
Mukhopadhyay, Partha; Baggelaar, Marc; Erdelyi, Katalin et al. (2016) The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol 173:446-58
Xu, Changqing; Hermes, Douglas J; Mackie, Ken et al. (2016) Cannabinoids Occlude the HIV-1 Tat-Induced Decrease in GABAergic Neurotransmission in Prefrontal Cortex Slices. J Neuroimmune Pharmacol 11:316-31
Alajaji, Mai; Lazenka, Matthew F; Kota, Dena et al. (2016) Early adolescent nicotine exposure affects later-life cocaine reward in mice. Neuropharmacology 105:308-17
Grim, Travis W; Samano, Kimberly L; Ignatowska-Jankowska, Bogna et al. (2016) Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497. J Basic Clin Physiol Pharmacol 27:217-28

Showing the most recent 10 out of 63 publications